期刊文献+

雄激素受体、Stathmin与三阴性乳腺癌临床病理因素相关性的初步探讨 被引量:2

Preliminary Study of Correlation Between Androgen or Stathmin Expression in Patients with Triple Negative Breast Cancer and Its Clinicopathologic Factors
原文传递
导出
摘要 目的探讨雄激素受体(AR)和Stathmin在三阴性乳腺癌患者中的表达情况并分析此与临床病理因素的相关性。方法回顾性收集2005~2009年期间在四川省人民医院乳腺外科确诊为三阴性乳腺癌并符合纳入条件患者共83例。使用免疫组织化学EnVision二步法检测AR和Stathmin蛋白在三阴性乳腺癌中的表达情况。用Spearman检验分析AR和Stathmin表达与患者年龄、肿瘤大小、淋巴结状态及病理分级的相关性。结果 AR和Stathmin在三阴性乳腺癌组织中表达阳性率分别为37.3%(31/83)和98.8%(82/83)。AR的表达与年龄呈正相关(rs=0.302,P=0.006),与肿瘤病理分级也呈正相关(rs=0.225,P=0.041),而与肿瘤大小和淋巴结状态无关(P>0.05)。Stathmin的表达与患者年龄、肿瘤大小、淋巴结状态及病理分级均无关(P>0.05)。结论 AR表达与乳腺癌患者的年龄及肿瘤分级有关,而Stathmin与生物学行为无关,其作为三阴性乳腺癌预后判断指标还需要进一步研究。 Objective To explore the expressions of androgen(AR)and Stathmin in triple negative breast cancer(TNBC)and analyze the correlation between these expressions and clinicopathologic features.Methods Eighty-three patients who were diagnosed as TNBC and met the inclusion criteria from 2005 to 2009 in the Sichuan Provincial People’s Hospital were collected retrospectively.The expressions of AR and Stathmin in the TNBC tissues by using the method of EnVision immunohistochemistry.The correlation between AR or Stathmin expression and age,tumor size,lymph node status,or histological grade was analyzed by Spearman test.Results The AR and Stathmin positive expression rates in the patients with TNBC were 37.3%(31/83)and 98.8%(82/83),respectively.The AR expression was positively correlated with age(r s =0.302,P=0.006)and pathological grade(r s =0.225,P=0.041),but was not correlated with tumor size or lymph node status.The Stathmin expression was not correlated with age,tumor size,lymph node status,or pathological grade(P0.05).Conclusions The AR expression is correlated with the age or pathological grade but Stathmin expression was all not correlated with the clinicopathologic features.AR or Stathmin as a prognosis indicator in patients with TNBC are needed to more research.
出处 《中国普外基础与临床杂志》 CAS 2013年第8期846-850,共5页 Chinese Journal of Bases and Clinics In General Surgery
关键词 三阴性乳腺癌 雄激素受体 STATHMIN 免疫组织化学 临床病理因素 Triple negative breast cancer Androgen receptor Stathmin Immunohistochemistry Clinicopathologic factor
  • 相关文献

参考文献29

  • 1Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breastcancer-current status and future directions [J]. Ann Oncol, 2009, 20(12): 1913-1927.
  • 2Medioni J, Huchon C, Le Frere-Belda MA, et al. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epiru- bicin for operable breast cancer: improved prognosis in triple- negative tumors [J]. DrugsRD, 2011, 11(2): 147-157.
  • 3Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [J]. J Clin Oncol, 2008, 26(8): 1275-1281.
  • 4Hanley K, Wang J, Bourne P, et al. Lack of expression of andr- ogen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast [J]. Hum Pathol, 2008, 39(3): 386-392.
  • 5Pristauz G, Petru E, Stacher E, et al. Androgen receptor expres- sion in breast cancer patients tested for BRCA1 and BRCA2 muta- tions [J]. Histopathology, 2010, 57(6): 877-884.
  • 6Tang D, Xu S, Zhang Q, et al. The expression and clinical significance of the androgen receptor and E-cadherin in triple- negative breast cancer [J]. Med Oneol, 2012, 29(2): 526-533.
  • 7Doane AS, Danso M, Lal P, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated tran- scriptional program and response to androgen [J]. Oncogene, 2006, 25(28): 3994-4008.
  • 8Agoff SN, Swanson PE, Linden H, et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immuno- histochemical, clinical, and prognostic associations [J]. Am J Clin Pathol, 2003, 120(5): 725-731.
  • 9Brattsand G. Correlation ofoncoprotein 18/stathmin expression in human breast cancer with established prognostic factors [J]. Br J Cancer, 2000, 83(3): 311-318.
  • 10Baquero MT, Hanna JA, Neumeister V, et al. Stathmin expres- sion and its relationship to microtubule-associated protein tan and outcome in breast cancer [J]. Cancer, 2012, 118(19): 4660- 4669.

同被引文献15

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部